EVAXEvaxion Biotech A/S

$20M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$2M-57.4% margin

Net Income

-$2M-64.1% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

+1859.1%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$15M

Total Liabilities

$15M

Stockholders' Equity

$74,000

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$2M	-$6M	+70.0%
Net Income	-$2M	-$6M	+65.9%

EVAX Q3 2024 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena